3 752

Cited 9 times in

Effect of warfarin withdrawal on thrombolytic treatment in patients with ischaemic stroke.

DC Field Value Language
dc.contributor.author김영대-
dc.contributor.author남정모-
dc.contributor.author남효석-
dc.contributor.author양재훈-
dc.contributor.author이경열-
dc.contributor.author정요한-
dc.contributor.author조한진-
dc.contributor.author차명진-
dc.contributor.author최혜연-
dc.contributor.author허지회-
dc.date.accessioned2014-12-20T16:59:17Z-
dc.date.available2014-12-20T16:59:17Z-
dc.date.issued2011-
dc.identifier.issn1351-5101-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/93756-
dc.description.abstractBACKGROUND AND PURPOSE:   Abruptly discontinuing warfarin may induce a rebound prothrombotic state. Thrombolytic agents may also paradoxically induce prothrombotic conditions, which include platelet activation and thrombin generation. Therefore, prothrombotic states may be enhanced by withdrawing warfarin in patients under thrombolytic treatment. This study was aimed to determine whether patients with warfarin withdrawal have different clinical outcomes from those without warfarin use after thrombolytic treatment. METHODS:   A total of 148 consecutive patients with atrial fibrillation who were not on anticoagulants at admission and who received thrombolysis were included in this study. We compared the outcomes between a warfarin withdrawal group and a no-warfarin group. RESULTS:   Fourteen patients (9.5%) were included in the warfarin withdrawal group. Although baseline National Institute of Health Stroke Scale (NIHSS) scores, recanalization rates, and hemorrhage frequencies did not differ between the groups, the warfarin withdrawal group showed poorer outcomes. Increased NIHSS scores during the first 7days were more frequent in the warfarin withdrawal group (57.1% vs. 26.9%, P=0.029). The median percent improvement in NIHSS scores at 24h after thrombolysis was also lower in the warfarin withdrawal group. After adjusting for covariates, warfarin withdrawal was a strong predictor of poor functional outcome at 3months (modified Rankin score≥3) (odds ratio, 17.067, 95% CI 2.703-107.748). CONCLUSIONS:   Discontinuing warfarin was associated with early neurologic deterioration and poor long-term outcomes after thrombolytic treatment.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1165~1170-
dc.relation.isPartOfEUROPEAN JOURNAL OF NEUROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAnticoagulants/therapeutic use*-
dc.subject.MESHAtrial Fibrillation/drug therapy-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRecovery of Function/drug effects*-
dc.subject.MESHStroke/drug therapy*-
dc.subject.MESHThrombolytic Therapy/adverse effects*-
dc.subject.MESHTissue Plasminogen Activator/adverse effects-
dc.subject.MESHUrokinase-Type Plasminogen Activator/adverse effects-
dc.subject.MESHWarfarin/therapeutic use*-
dc.titleEffect of warfarin withdrawal on thrombolytic treatment in patients with ischaemic stroke.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Preventive Medicine (예방의학)-
dc.contributor.googleauthorY. D. Kim-
dc.contributor.googleauthorJ. H. Lee-
dc.contributor.googleauthorY. H. Jung-
dc.contributor.googleauthorM.-J. Cha-
dc.contributor.googleauthorH. Y. Choi-
dc.contributor.googleauthorC. M. Nam-
dc.contributor.googleauthorJ. H. Yang-
dc.contributor.googleauthorH. J. Cho-
dc.contributor.googleauthorH. S. Nam-
dc.contributor.googleauthorK.-Y. Lee-
dc.contributor.googleauthorJ. H. Heo-
dc.identifier.doi10.1111/j.1468-1331.2011.03363.x-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00702-
dc.contributor.localIdA01264-
dc.contributor.localIdA01273-
dc.contributor.localIdA02318-
dc.contributor.localIdA02648-
dc.contributor.localIdA03659-
dc.contributor.localIdA03922-
dc.contributor.localIdA03993-
dc.contributor.localIdA04217-
dc.contributor.localIdA04369-
dc.relation.journalcodeJ00830-
dc.identifier.eissn1468-1331-
dc.identifier.pmid21314856-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1111/j.1468-1331.2011.03363.x/abstract-
dc.subject.keywordanticoagulation-
dc.subject.keywordatrialfibrillation-
dc.subject.keywordprognosis-
dc.subject.keywordstroke-
dc.subject.keywordthrombolysis-
dc.contributor.alternativeNameKim, Young Dae-
dc.contributor.alternativeNameNam, Jung Mo-
dc.contributor.alternativeNameNam, Hyo Suk-
dc.contributor.alternativeNameYang, Jae Hoon-
dc.contributor.alternativeNameLee, Kyung Yul-
dc.contributor.alternativeNameJung, Yo Han-
dc.contributor.alternativeNameCho, Han Jin-
dc.contributor.alternativeNameCha, Myoung Jin-
dc.contributor.alternativeNameChoi, Hye Yoen-
dc.contributor.alternativeNameHeo, Ji Hoe-
dc.contributor.affiliatedAuthorKim, Young Dae-
dc.contributor.affiliatedAuthorNam, Jung Mo-
dc.contributor.affiliatedAuthorNam, Hyo Suk-
dc.contributor.affiliatedAuthorYang, Jae Hoon-
dc.contributor.affiliatedAuthorLee, Kyung Yul-
dc.contributor.affiliatedAuthorJung, Yo Han-
dc.contributor.affiliatedAuthorCho, Han Jin-
dc.contributor.affiliatedAuthorCha, Myoung Jin-
dc.contributor.affiliatedAuthorChoi, Hye Yoen-
dc.contributor.affiliatedAuthorHeo, Ji Hoe-
dc.rights.accessRightsnot free-
dc.citation.volume18-
dc.citation.number9-
dc.citation.startPage1165-
dc.citation.endPage1170-
dc.identifier.bibliographicCitationEUROPEAN JOURNAL OF NEUROLOGY, Vol.18(9) : 1165-1170, 2011-
dc.identifier.rimsid28440-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.